ContextLoss of viral suppression in patients infected with human immunodeficiency virus
(HIV), who are receiving potent antiretroviral therapy, has been attributed to outgrowth of …

Background: Antiretroviral regimens containing HIV protease inhibitors suppress viremia in
HIV-infected patients, but the durability of this effect is not known. Objective: To describe the …

Residual viremia can be detected in most HIV-1-infected patients on antiretroviral therapy
despite suppression of plasma RNA to< 50 copies per ml, but the source and duration of this …

In HIV-1-infected individuals on currently recommended antiretroviral therapy (ART), viremia
is reduced to< 50 copies of HIV-1 RNA per milliliter, but low-level residual viremia appears …

ContextAbacavir, a nucleoside analogue, has demonstrated suppression of human
immunodeficiency virus (HIV) replication alone and in combination therapy. However, the …

Objective: To compare the viral suppression of two antiretroviral regimens using three drugs
or five drugs. Design: Two open-label studies using a three-drug (zidovudine, lamivudine …

ContextIn HIV-infected patients having virologic suppression (plasma HIV RNA< 50
copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been …

Background: Markers are needed for assessing response to antiretroviral therapy over time.
The CD4+ lymphocyte count is one such surrogate, but it is relatively weak. Objective: To …

Objective Although highly active antiretroviral therapy has been shown to lower plasma HIV-
1 RNA in HIV infection, many patients do not reach the target goal of undetectable viremia …

Background: Current guidelines state that the goal of antiretroviral therapy for HIV-infected
individuals is to suppress plasma viral load (pVL) to below 400 copies/ml Methods …